95 related articles for article (PubMed ID: 21782528)
1. Modeling Alzheimer's disease progression using the disease system analysis approach.
Gomeni R; Simeoni M; Zvartau-Hind M; Irizarry MC; Austin D; Gold M
Alzheimers Dement; 2012 Jan; 8(1):39-50. PubMed ID: 21782528
[TBL] [Abstract][Full Text] [Related]
2. Quantification of disease progression and dropout for Alzheimer's disease.
William-Faltaos D; Chen Y; Wang Y; Gobburu J; Zhu H
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):120-31. PubMed ID: 23211395
[TBL] [Abstract][Full Text] [Related]
3. Disease progression meta-analysis model in Alzheimer's disease.
Ito K; Ahadieh S; Corrigan B; French J; Fullerton T; Tensfeldt T;
Alzheimers Dement; 2010 Jan; 6(1):39-53. PubMed ID: 19592311
[TBL] [Abstract][Full Text] [Related]
4. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
5. Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease.
Velayudhan L; Proitsi P; Westman E; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Spenger C; Hodges A; Powell J; Lovestone S; Simmons A;
J Alzheimers Dis; 2013; 33(3):755-66. PubMed ID: 23047370
[TBL] [Abstract][Full Text] [Related]
6. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
[TBL] [Abstract][Full Text] [Related]
8. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Frölich L; Ashwood T; Nilsson J; Eckerwall G;
J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
[TBL] [Abstract][Full Text] [Related]
9. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
10. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Wiig EH; Annas P; Basun H; Andreasen N; Lannfelt L; Zetterberg H; Blennow K; Minthon L
Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
[TBL] [Abstract][Full Text] [Related]
11. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database.
Ito K; Corrigan B; Zhao Q; French J; Miller R; Soares H; Katz E; Nicholas T; Billing B; Anziano R; Fullerton T;
Alzheimers Dement; 2011 Mar; 7(2):151-60. PubMed ID: 20810324
[TBL] [Abstract][Full Text] [Related]
12. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
13. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
14. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population.
Hannesdóttir K; Snaedal J
Nord J Psychiatry; 2002; 56(3):201-6. PubMed ID: 12079572
[TBL] [Abstract][Full Text] [Related]
15. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
Vellas B; Andrieu S; Cantet C; Dartigues JF; Gauthier S
J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
[TBL] [Abstract][Full Text] [Related]
16. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
[TBL] [Abstract][Full Text] [Related]
17. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Wesnes K; Edgar C; Andreasen N; Annas P; Basun H; Lannfelt L; Zetterberg H; Blennow K; Minthon L
Acta Neurol Scand; 2010 Oct; 122(4):270-7. PubMed ID: 20047570
[TBL] [Abstract][Full Text] [Related]
18. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
Wattmo C; Wallin ÅK
Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
